Hepatitis C News

The incidence of lymphoma — Hodgkin and non-Hodgkin — was up to 15 times higher among patents with HIV monoinfection and HIV/hepatitis C virus coinfection compared with the general population, according to findings presented at the International Liver Congress in Paris.

PARIS — Although sustained virologic response maintained a high level no matter the alcohol or cannabis consumption in a German registry, those who reported drinking alcohol in excess were more likely to be lost to follow-up, according to a presentation at the International Liver Congress 2018.

PARIS — Though some direct-acting antivirals conflict with the administration of hormone replacement therapy or oral contraceptives, a recent study showed safety and efficacy with Zepatier, according to a our exclusive interview with Christophe Hezode, MD, at the International Liver Congress 2018.

PARIS — Researchers evaluated the cost-effectiveness of regular hepatocellular carcinoma screening among patients with hepatitis C after sustained virologic response. In this exclusive video from the International Liver Congress 2018, Hooman Farhang Zangneh, MD, MSc, discusses the thresholds and limitations for cost-effective liver cancer screening.

PARIS — Using a new medication and generic sofosbuvir, researchers reached 97% sustained virologic response in patients with hepatitis C both with and without cirrhosis; in this exclusive video from the International Liver Congress 2018, Drugs for Neglected Diseases Initiative (DNDi) addresses the impact of this research.

PARIS — Two real-world studies presented at the International Liver Congress 2018 confirmed the efficacy and safety of Mavyret in Italy and Germany even in the face of multiple comorbidities.

PARIS — Treating hepatitis C virus in the early stage of disease saves money in drug and medical costs while lowering risk for decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver-related death, according to a presentation at the International Liver Congress 2018.

PARIS — Beginning Wednesday, April 11, Healio Gastroenterology and Liver Disease will provide live coverage from the International Liver Congress 2018.

Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially hepatocellular carcinoma. Recent studies have focused on defining liver cancer risks related to HCV progression and the rates of liver cancer after HCV clearance with new direct-acting antivirals.

A novel point-of-care test for hepatitis C meets the recent Foundation for Innovation in New Diagnostics and World Health Organization’s Target Product Profile for HCV decentralized testing in low-income and middle-income countries, according to a recently published study.